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ABSTRACT
Atherosclerotic renal artery stenosis can cause ischaemic ne-
phropathy and arterial hypertension. We herein review the ob-
servational and randomized clinical trials (RCTs) comparing
medical and endovascular treatment for control of hyperten-
sion and renal function preservation. Using the Population
Intervention Comparison Outcome (PICO) strategy, we ident-
iﬁed the relevant studies and performed a novel meta-analysis
of all RCTs to determine the efﬁcacy and safety of endovas-
cular treatment when compared with medical therapy. The
following outcomes were examined: baseline follow-up differ-
ence in mean systolic and diastolic blood pressure (BP), serum
creatinine, number of drugs at follow-up, incident events
(heart failure, stroke, and worsening renal function), mortality,
cumulative relative risk of heart failure, stroke, and worsening
renal function. Seven studies comprising a total of 2155
patients (1741 available at follow-up) were considered, includ-
ing the recently reported CORAL Study. Compared with
baseline, diastolic BP fell more at follow-up in patients in the
endovascular than in the medical treatment arm (standard
difference in means −0.21, 95% conﬁdence interval (CI):
−0.342 to −0.078, P = 0.002) despite a greater reduction in
the mean number of antihypertensive drugs (standard differ-
ence in means −0.201, 95% CI: −0.302 to −0.1, P < 0.001). At
variance, follow-up changes (from baseline) of systolic BP,
serum creatinine, and incident cardiovascular event rates did
not differ between treatment arms. Thus, patients with ather-
osclerotic renal artery stenosis receiving endovascular treat-
ment required less anti-antihypertensive drugs at follow-up
than those medically treated. Notwithstanding this, they evi-
denced a better control of diastolic BP.
Keywords: controlled randomized clinical trials, renal artery
stenosis, renovascular hypertension, transluminal angioplasty
INTRODUCTION
Atherosclerotic renal artery stenoses (ARAS) are increasingly
found due to ageing of the population and account for ∼90% of
all renal artery lesions [1]. They have several nefarious effects,
including inﬂammation, oxidative stress, and endothelial dys-
function, and thus can lead to ischaemic nephropathy and,
through the activation of the renin–angiotensin–aldosterone
system, to high blood pressure (BP) and to widespread cardio-
vascular disease [2]. It is generally held that a stenosis attains
haemodynamic signiﬁcance only when the luminal narrowing
is at least 70%, when compared with the nearby unaffected
vessel or, if between 50 and 70%, when the trans-stenotic peak
or mean pressure gradient is >20 or >10 mmHg, respectively
[3]. All these threshold values are, however, to be regarded cau-
tiously because of the difﬁculty of measuring precisely the renal
artery narrowing due to marginal blurring and/or selection of a
reliable reference point, and also to the fact that an accurate
estimation of the degree of narrowing would require a 3D re-
construction of the vessel lumen, which has never been
exploited in clinical studies in this ﬁeld thus far. In most of
these studies, estimates were obtained on planar images, which
can lead to over- or under-estimation depending on the orthog-
onal projection chosen [4].
© The Author 2014. Published by Oxford University Press
on behalf of ERA-EDTA. All rights reserved.
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Until 1978, when Grüntzig introduced percutaneous trans-
luminal coronary angioplasty (PTCA) [5], patients with ARAS
were treated medically or surgically. A wide array of observa-
tional, retrospective, and controlled trials thereafter suggested
that PTRA could be beneﬁcial over medical treatment for pre-
serving renal function and improving BP control (Tables 1
and 2) [6–17]. Accumulated experience, however, showed that
PTRA was hampered by a high rate of restenosis in ARAS
patients [9, 18, 19]. Moreover, randomized clinical trials
(RCTs) that compared medical therapy with PTRA could not
prove the superiority of the latter for controlling hypertension
and preserving renal function [18, 20, 21]. Stenting was intro-
duced as a valuable addition to PTRA [22], but not even PTRA
plus stenting (PTRAS) could unequivocally be shown to over-
come medical therapy in the very few available RCTs [23–25]
(Tables 3–5). These trials, however, had limitations in study
design and treatment options, which overall led to challenging
their results and conclusions. Accordingly, available guidelines
on treatment of ARAS could not be based on class I level of
evidence A [26]. Therefore, the optimal treatment of ARAS
patients remains a highly controversial issue among physicians,
which translates into ample variation in clinical practice.
To the aim of highlighting current evidences on the manage-
ment of ARAS patients, we will ﬁrst review the results of obser-
vational studies and published meta-analyses of available RCTs
that compared PTRAS with medical treatment. We will then
report on the results of a novel meta-analysis that was based on
criteria that differed from the previous ones and furthermore
comprised a yet unpublished RCT [27], alongside the recently
reported CORAL study [25].
METHODS
A Medline search of the English-language literature published
from January 1995 to November 2013 using the Population In-
tervention Comparison Outcome (PICO) strategy [28] and the
keywords reported in the Supplementary data was performed to
identify the cohort studies and the RCT on renal arterial revas-
cularization with PTRA, alone or associated with stenting.
Observational studies
We found three retrospective and nine prospective cohort
studies (Tables 1 and 2) that investigated the usefulness of
PTRA alone or of PTRAS. Among the retrospective studies,
two evaluated the effect of revascularization on renal function in
chronic kidney disease (CKD) patients. In one study, 99 patients
with an eGFR of <80 mL/min treated with PTRA were divided
into two groups: those with poorly controlled BP and those with
rapid deteriorating renal function. In the latter group, most
ARAS were either bilateral or in a solitary kidney. After 29 ± 10
months of follow-up, the patients with rapid deteriorating renal
Table 1. Clinical retrospective studies on PTRA ± stenting outcome in ARAS patients
Reference Sample
size (n)
Population Intervention Primary endpoint Renal function
outcomes
Blood pressure outcomes
Cognet
et al. 2001
[6]
99 • ARAS >70%
• GFR <80 mL/min
– Group A: stable CKD
– Group B: rapid
worsening renal
function
PTRA ± stent 10% variation versus baseline
in GFR
• No differences
between baseline
and ﬁnal GFR in
overall population
• Larger GFR gain
in Group B than
in Group A
Alhadad
et al. 2009
[7]
234 Signiﬁcant ARAS PTRA • BP cure (DBP <90 and
SBP <140 mmHg off
antihypertensive drugs)
• BP improvement (DBP
<90 mmHg and/or SBP
<140 mmHg on the same
or reduced number of
drugs, or reduction in DBP
of ≥15 mmHg with the
same or reduced number
of drugs)
• SBP and DBP decrease
• Decrease in
antihypertensive drugs
Dichtel
et al. 2010
[8]
118 • ARAS >75%
• Moderate-to-severe
CKD (GFR >15 and
<60 mL/min/1.73 m2)
• Medical
therapy
(n = 71)
• PTRA ± stent
(n = 47)
Change in GFR over the
ﬁrst year after diagnosis/
treatment
No GFR difference
between the two
groups
• No difference in SBP and
DBP between the two
groups
• Number of
antihypertensive drugs in
medical group
signiﬁcantly higher than
in PTRA group at 12
months. Difference
disappeared at 24 and 36
months
BP, blood pressure; CKD, chronic kidney disease; DBP, diastolic blood pressure; DDD, deﬁned daily dose; PTRA, percutaneous transluminal renal angioplasty; SBP, systolic blood
pressure; SCr, serum creatinine.
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Table 2. Clinical prospective studies on PTRA ± stenting outcome in ARAS patients
Reference Sample
size (n)
Population Intervention Primary endpoints Renal function outcomes Blood pressure
outcomes
Harden et al. [9] 32 • CKD
• ARAS >50%
PTRA + stent • 20% change in SCr from
baseline
• Renal replacement therapy
• Death
• 34% improved, 34%
stabilized, 28%
worsened
• Progression of renal
failure slower after
PTRA
• DBP decrease after
PTRA
• No difference in
SBP
• No difference in
antihypertensive
drugs
Watson et al. [10] 33 • CKD
• Bilateral
stenosis or
unilateral
stenosis in
SFK
PTRA ± stent Slopes of 1/SCr before and
after PTRA
Mean slope increased after
PTRA
• SBP and DBP
decrease after
PTRA
• No difference in
antihypertensive
drugs
Muray et al. [11] 59 • CKD
• ARAS >60%
PTRA Slopes of 1/SCr before and
after PTRA
• Renal function
improved in 58% and
stabilized or worsened
in 42% of patients
• Slope of 1/SCr before
PTRA associated with
a favorable change in
progression rate after
PTRA
Leertouwer et al. [12] 18 ARAS ≥50% PTRA ± stent Single-kidney contributions
to the total renin secretion,
effective plasma ﬂow
(131I-hippuran clearance)
and (125I-thalamate
clearance)
• Vein-to-artery renin
ratio at treated side
decreased
• 131I-hippuran
improvement at treated
side and contra-
laterally
• 125I-thalamate
improvement at treated
side and contra-
laterally
Coen et al. [13] 46 • CKD
• Unilateral
ARAS
PTRA ± stent
(n = 27)
Medical therapy
(n = 19)
• eGFR
• GFR based on NAFS
• No eGFR difference in
the two groups
• GFR increase in PTRA
kidney and decrease in
contralateral based on
NAFS
• SBP and DBP
decrease in PTRA
patients
• Decrease in
antihypertensive
drugs at 3 and 6
months after
PTRA
Zeller et al. [14] 215 ARAS ≥70% PTRA ± stent • SCr
• Mean BP by 24-h
monitoring
SCr decrease at 1 year Mean arterial BP
decrease at 1 year
Zeller et al. [15] 340 ARAS ≥70% PTRA ± stent • 10% decrease in SCr
• eGFR
• SCr decrease
• No difference in eGFR
SBP, DBP and mean
BP improve after
PTRA
Rivolta et al. [16] 52 CKD PTRA ± stent Slopes of 1/SCr before
and after PTRAS
Improvement in renal
function in 15.5% patients,
stable renal function in
59.5%, reduction in renal
function in 25%
Kalra et al. [17] 908 • ARAS >60%
• ARAS 50–
60% with
post-stenotic
dilatation
• PTRA ± stent
(n = 561)
• Medical
therapy
(n = 347)
• eGFR
• BP
• No eGFR difference in
the two groups
• eGFR increase in
PTRAS compared with
the non-PTRAS
patients with CKD
stage 4 and 5
• No difference in
BP control in the
two groups
• BP decrease in the
overall groups and
within each CKD
category
BP, blood pressure; CKD, chronic kidney disease; DBP, diastolic blood pressure; NAFS, nephroangiophotoscintigraphy; PTRAS, percutaneous transluminal renal angioplasty plus
stenting; SBP, systolic blood pressure; SCr, serum creatinine; SFK, single functioning kidney.
F
U
L
L
R
E
V
IE
W
A t h e r o s c l e r o t i c r e n o v a s c u l a r h y p e r t e n s i o n 543
 at U
niversitÃ  degli Studi di Padova on June 27, 2015
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
Table 3. Randomized clinical trials characteristics: deﬁnition of ARAS and inclusion/exclusion criteria
Study name
(year)
Deﬁnition of ‘Substantial’
ARAS
Inclusion criteria Exclusion criteria
EMMA (1998) Unilateral ≥75% without
thrombosis or ≥60% with
positive lateralization testa
• DBP >95 mmHg
• GFR ≥50 mL/min
• Malignant hypertension
• Stroke or AMI in previous 6 months
• Pulmonary oedema
• DBP >109 mmHg at end of run-in
SNRASCG
(1998)
Uni- or bilateral ≥50% DBP >95 mmHg with at least two drugs • SCr >500 µmol/L
• Stroke or AMI in previous 3 months
DRASTIC
(2000)
Uni- or bilateral ≥50% DBP >95 mmHg with at least two drugs • SCr >200 µmol/L
• Cancer
• Other forms of secondary hypertension
• HF or unstable angina
• Single kidney with SCr >150 µmol/L
• Stenotic kidney <8 cm
• Renal artery occlusion
• Aortic aneurism needing surgery
STAR (2009) Uni- or bilateral ≥50% GFR (Cockcroft Gault) <80 mL/min • Stenotic kidney <8 cm
• Renal artery <4 mm
• GFR <15 mL/min
• Diabetes with proteinuria >3 g/die
• Malignant hypertension
ASTRAL
(2009)
Uni- or bilateral ‘substantial
anatomical stenosis’
‘If the patient’s doctor was uncertain that the patient would
deﬁnitely have a worthwhile clinical beneﬁt
from revascularization’
• Need of surgery or high revascularization
probability in 6 months
• Non-atherosclerotic cardiac disease
• Previous renal revascularization
NITER not
published
Uni- or bilateral ≥70% • SCr ≤ 3 mg/dL and/or GFR (MDRD) ≥30 mL/min
• Stenotic kidney ≥8 cm
• BP≤ 150/90 mmHg with <4 drugs
• Other cause of CKF
• Doppler renal resistance index >0.8
• Renal artery occlusion
• Cerebro- or cardiovascular disease in previous 6
months
• Cancer with estimated life <1 year
• Cholesterol thrombo-embolization episodes
• Hepatic failure
• HF (NYHA IV) or unstable angina
• Intolerance to iodinated contrast, statin
or antiplatelets
CORAL (2013) Uni- or bilateral with:
• ≥60% with a ≥20 mmHg
systolic pressure gradient,
or
• if ≥80% (no pressure
gradient required)
SBP ≥155 mmHg on ≥2 drugs • DBP ≥120 mmHg and/or SBP ≥200 mmHg
• Stroke or TIA within 3 months or known
carotid stenosis ≥70%
• Major surgery, trauma, revascularization
procedure, unstable angina or AMI in previous
30 days
• Hospitalization for HF within 3 months
• Ejection fraction <30%
• Diabetes with either:
a. Proliferative retinopathy and ≥1 + protein
on urine dipstick or
b. ≥1 + protein on urine dipstick and urine
protein/Cr ratio >0.5
• Kidney size <8 cm
• SCr >3.0 mg/dL
• Aneurysm of the abdominal aorta >4.0 cm
• Previous renal artery bypass surgery or
angioplasty or stent intervention or kidney
transplant
• Intolerance to iodinated contrast, statin
or antiplatelets
AMI, acute myocardial infarction; BP, blood pressure; CKF, chronic kidney failure; DBP, diastolic BP; GFR, glomerular ﬁltration rate; HF, heart failure; SCr, serum
creatinine.
avenous pielography, renal scintigraphy and renal venous renin concentration.
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function had a greater gain in creatinine clearance than those
with poor BP control and stable CKD [6]. In another study of
118 ARAS patients with an average baseline GFR of 37 ± 15 mL/
min/1.73 m2, 71 were treated medically and 47 with PTRAS.
They were assigned to either treatment by each patient’s clinician
at the time of presentation without predetermined criteria. After
34-month follow-up, both groups showed a similar decline in
GFR, systolic and diastolic BP values, and a superimposable
change in number of drugs prescribed from diagnosis [8].
We could identify nine studies with a prospective design on a
total of 1703 patients [9–17] (Table 2). They differed for
inclusion criteria, primary endpoints and, moreover, sample size,
which ranged from 18 to 908 patients. Only three studies en-
rolled >100 patients and all of them reported a signiﬁcantly fall
Table 4. Randomized clinical trials characteristics: endpoints, follow-up timing and types of analysis
Study
name
Primary endpoints Secondary endpoints Follow-up
(months)
Intention-
to-treat
Crossing-
over No. (%)
Stenting
(%)
Bilateral
stenosis (%)
EMMA BP by means of ABPM • Number of drugs
• Complications
6 No 7 (27%) 8.7 0
SNRASCG • OBP
• SCr
• Number of drugs
• Events
• Complications
12 No 0 0 50.9
DRASTIC OBP • Number of drugs
• SCr
• GFR
• Renal scintigraphy
• Restenosis
• Complications
12 Yes 22 (44%) 3.6 22.6
STAR GFR increase ≥20% • OBP
• Complication
• Malignant hypertension
• Pulmonary oedema
• Cardiovascular morbility
and mortality
24 Yes 1 (1.3%) 71.8 48
ASTRAL Mean slope of the reciprocal of serum
SCr over time
• OBP
• Time-to-ﬁrst renal event
• Time to ﬁrst major
cardiovascular event
• Mortality
60 Yes 24 (6%) 95 53.5
NITER • Mortality
• Dialysis
• SCr increase of >20% or GFR (MDRD)
decrease of >20% at 0.5, 1 and 2 years
with an extended 2-year follow-up
• SBP and DBP at 0.5, 1
and 2 years with an
extended 2-year follow-
up
• Number of drugs
• Renal scintigraphy
• Complications due to
interventional maneuvers
• Incidence of extra-renal
vascular complications
42 n.a. (1.9%) 100 51.5
CORAL Event-free survival from cardiovascular
and renal adverse events (composite of
cardiovascular or renal death, stroke, AMI,
hospitalization for HF, progressive renal
insufﬁciency or need for permanent renal
replacement therapy)
• All-cause mortality
• Longitudinal kidney
function (1/Cr)
• SBP
• Durability of renal artery
patency
• Renal resistive index
• Correlation between
stenosis severity and
kidney function (1/Cr)
• Quality of life
• Cost-effectiveness
60 Yes 19 (4%) 100 20
ABPM, ambulatory BP monitoring; AMI, acute myocardial infarction; BP, blood pressure; DBP, diastolic BP; GFR, glomerular ﬁltration rate; HF, heart failure; SBP, systolic BP;
SCr, serum creatinine; n.a., not available.
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in mean BP of ∼10 mmHg after PTRA ± stenting [14, 15, 17].
However, only one study [17], which enrolled 908 patients, com-
pared two groups of patients according to assignment either to
medical treatment or PTRAS. This study reported no differ-
ences between treatment arms in BP fall and changes in eGFR.
With the exception of patients with CKD stage 4 and 5, eGFR
failed to improve signiﬁcantly in the PTRAS compared with the
medical arm [17]. In the other two larger studies, a decrease
of sCr was seen [14, 15], but the 1-year decrease was border-
line signiﬁcant in both (P = 0.047 and P = 0.048); mean BP
decreased signiﬁcantly by ∼10 mmHg in both studies.
Among the smaller studies, the majority showed a decrease
of BP and an improvement of renal function with PTRAS.
However, only one compared PTRAS and medical treatment
in patients with unilateral ARAS and found a signiﬁcant drop
in BP (systolic and diastolic) from baseline after one year,
along with a signiﬁcant fall in number of antihypertensive
drugs in the PTRAS patients with no change in the medical
treatment arm.
On the whole, these studies showed an improvement of
renal function in 58% and a better BP control in 67% of the
patients with PTRAS (see Supplementary data), thus support-
ing the conclusion that PTRA with or without stenting does
not preclude achievement of a better control of BP and/or
does not harm the kidney, but, rather the opposite. However,
by no means does this allow the conclusion that revasculariza-
tion is better than medical therapy for preservation of renal
function and BP control.
Randomized clinical trials
We could identify eight RCTs comparing medical treat-
ment and revascularization in ARAS patients, one of which is
yet to be published and one, the METRAS [29], still recruiting.
Besides an ample variation in the number of recruited patients,
the seven already completed showed heterogeneity of inclusion
and exclusion criteria, primary and secondary endpoints, and
follow-up time. Nonetheless, they lent themselves to a meta-
analysis and some of them were in fact included in four pub-
lished meta-analyses [30–33].
By meta-analysing the same three trials for changes (from
baseline) of BP and sCr at 6 months (on 210 patients in
studies published until 2003), two of these four meta-analyses
found a greater reduction in systolic and diastolic BP (P < 0.05)
and a trend (P = 0.06) toward a beneﬁt in terms of changes in
sCr in the PTRA arm [30, 31]. The other two compared PTRA
with/without stenting on top of medical therapy versus medical
management alone: Kumbhani et al. examined six RCTs (in
1208 patients) and found no between-arm differences in change
from baseline of systolic (weighted mean difference = 1.20
mmHg, 95% CI: −1.18 to 3.58 mmHg) or diastolic BP
(weighted mean difference =−1.60 mmHg, 95% CI: −4.22 to
1.02 mmHg). However, after 29-month follow-up, there was a
reduction in mean number of antihypertensive medications in
the PTRAS compared with the medically treated patients
(weighted mean difference =−0.26, 95% CI −0.39 to −0.13, P
< 0.001); sCr did not differ between arms at the end of follow-
up [32]. At variance, by meta-analysing ﬁve of the same six
trials on a total of 1030 patients, Shetty et al. found only a
trend toward an improvement in systolic, diastolic BP and sCr
in the patients assigned to PTRAS [33].
Of note, in all the meta-analysed RCTs, there was a high
rate of dropouts, which could have introduced a selection bias,
thus conceivably affecting their results. In fact, neither the
original studies nor their meta-analyses provided any evidence
that the patients available at follow-up were comparable with
those originally recruited and that the drop-out rate was com-
parable between treatment arms. Therefore, to minimize this
potential pitfall, unlike previous meta-analyses, we elected to
exclude those who dropped-out and to meta-analyse only the
patients available at baseline and at 1-year follow-up (Table 5).
Inclusion and exclusion criteria and data extraction
To be included in the meta-analysis, the RCT had to ran-
domly assign ARAS patients to either medical therapy alone
or to PTRA with/without stenting. Studies on ARAS patients
allocated to surgical treatment were excluded. Besides the six
published RCTs (SNRASCG [20], EMMA [18], DRASTIC [21],
STAR [23], ASTRAL [24], CORAL [25]) a yet unpublished
study (NITER [27]) could be included, as the relevant data were
kindly provided by the corresponding author.
The following features were examined for each eligible
study: number of patients, deﬁnition of signiﬁcant ARAS,
Table 5. Patients’ characteristics at baseline and follow-up
EMMA SNRASCG DRASTIC STAR ASTRAL NITER CORAL
Total number of PTS 49 55 106 140 806 52 947
Initial number of PTS (medical/endovascular) 26/23 30/25 50/56 76/64 403/403 24/28 480/467
Number of PTS at 1 year (medical/endovascular) n.a. 21/22 27/53 60/52 348/332 n.a. 371/362
Final number of PTS (medical/endovascular) 18/23 30/24 27/53 53/46 86/77 24/28 40/59
Age (years) 59.4 61 60 66.5 70.5 72 69
Baseline PAS (mmHg) (medical/endovascular) 149/151 175/182 180/179 163/160 152/149 148/149 150/150
Follow-up PAS (mmHg) (medical/endovascular) 141/140 169.5/166 159/160 155/151 148/146 139/146 135/133
Baseline PAD (mmHg) (medical/endovascular) 89/91 91.5/96.5 103/104 82/83 76/76 79/79 n.a.
Follow-up PAD (mmHg) (medical/endovascular) 84/81 91/86.5 91/93 79/77 75/73 74/81 n.a.
Baseline SCr (µmol/L) (medical/endovascular) 105/101 158/160 114/106 145/154 178/179 n.a. n.a.
Follow-up SCr (µmol/L) (medical/endovascular) 91/88 182/163.5 106/106 168/156 192/196 n.a. n.a.
Baseline No. drugs (medical/endovascular) n.a. 2.4/2.8 2/2 2.9/2.8 2.8/2.79 3.3/3.3 2.1/2.1
Follow-up No. drugs (medical/endovascular) n.a. 2.6/2.3 2.4/1.9 2.9/2.6 2.97/2.77 3.2/2.9 3.5/3.3
PTS, patients; ; SCr, serum creatinine; n.a., not available.
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percentage of patients with bilateral stenosis, age, comorbidities
(hypertension, diabetes mellitus, dyslipidaemia, coronary artery
disease, and stroke), risk factors (cigarette smoking), BP, renal
function (sCr), number of drugs at baseline, time to follow-up,
analysis type (per-protocol and intention-to-treat), drop-out and
crossover rate, technique used for BP measurement and for renal
function evaluation. The rate of stenting on the total of endovas-
cular procedures was also examined (Tables 3–5).
Endpoints
The outcomes analysed were as follows: between-treatment
arm difference in mean systolic and diastolic BP value; sCr; need
(number) of antihypertensive drugs at follow-up; incidence
of heart failure, stroke, worsening renal function, and death;
cumulative relative risk of such events.
Statistical analysis
To preserve the effect of randomization, we used an inten-
tion-to-treat analysis like in the previous meta-analyses.
However, we excluded dropouts beforehand and considered
only patients available at 1-year follow-up. At variance with
previous meta-analyses, we elected to use a commercially
available software package (Comprehensive Meta-analysis,
Statistical Solution, Biostat, Englewood, NJ, USA) to allow
for independent replication of results.
For continuous variables, the standard difference in mean
(SDM) and corresponding 95% conﬁdence interval were com-
puted using random-effects modelling. The variables for which
summary measures of spread (standard deviation or SEM) were
not reported in the original publications were excluded from
the meta-analysis. Heterogeneity was assessed using inconsis-
tency of treatment effects among trials (I2). The impact of
potential covariates was also examined using meta-regression
analysis. The statistical signiﬁcance (P-value) was set at 0.05.
RESULTS OF RANDOMIZED
CLINICAL TRIALS
Six published RCTs (SNRASCG [20], EMMA [18], DRASTIC
[21], STAR [23], ASTRAL [24], CORAL [25]) and one unpub-
lished study (NITER [27]) fulﬁlled the selection criteria and
could be included. Overall, a total of 2155 patients were en-
rolled, but only 81% were available at 1-year follow-up (872 ran-
domized to the endovascular treatment and 869 to the medical
therapy arm). As the trials had widely different sizes, which had
a marked impact on the outcome analysis, we calculated and
reported the relative weight of each trial for each endpoint
(Figure 1, Panels A–C). For clarity purposes, results of between-
treatment comparison for pre-speciﬁed outcomes (Table 6) are
herein reported in an itemized way.
Blood pressure, antihypertensive medications, and
serum creatinine
There was no evidence of among-study heterogeneity for
systolic or diastolic BP (I2 = 0) (Figure 1, Panels A and B). The
change of SBP from baseline to follow-up was similar in the
endovascular treatment and medical therapy arm (SDM
−0.048, 95% CI: −0.145 to 0.050, P = 0.338). At variance, the
reduction in diastolic BP was greater in the endovascular treat-
ment than in the medical therapy arm (SDM −0.210, 95% CI:
−0.342 and −0.078, P = 0.002).
This larger fall in diastolic BP occurred in spite of a greater
reduction in mean number of antihypertensive drugs from
baseline to follow-up in the endovascular than in the medi-
cal treatment arm (SDM −0.201, 95% CI: −0.302 and −0.100,
P < 0.001), with evidence of only mild heterogeneity among
studies (I2 = 1.214) (Figure 1, Panel C).
The change of sCr from baseline to follow-up did not differ
between treatment arms (SDM −0.099, 95% CI: −0.222 to
0.025, P = 0.119) (Figure 2). There was no evidence of hetero-
geneity among the studies (I2 = 0).
Worsening renal function, heart failure, stroke and all-
cause mortality
The incidence of worsening renal function was high but did
not differ between the endovascular treatment and the medical
therapy arm (13.7 versus 14.8%, respectively; RR = 0.893, 95%
CI: 0.701 to 1.136, P = 0.357).
The incidence of heart failure was lower in the endovascular
treatment than in the medical therapy arm (10.8 versus 13.6%,
respectively; RR = 0.863, 95% CI: 0.639 to 1.167, P = 0.339),
albeit not signiﬁcantly so. Stroke incidence (5.6 versus 6.1%,
respectively; RR = 0.819, 95% CI: 0.542 to 1.237, P = 0.342)
and all-cause death rate (21.8 versus 22.4%, RR = 0.894, 95%
CI: 0.709 to 1.127, P = 0.342) were similar in the two arms. For
none of these endpoints, was there evidence of heterogeneity
among the studies (I2 = 0).
The cumulative risk of incident CV and renal events did
not differ between the endovascular treatment and the medical
therapy arm (40.5 versus 44%, RR = 0.905, 95% CI: 0.751 to
1.090, P = 0.294); was there no evidence of heterogeneity among
the studies (I2 = 0).
Meta-regression
Meta-regression showed that the SDM of number of drugs
and percentage of diabetic patients reached statistical signiﬁ-
cance (Figure 3). This ﬁnding indicates that the beneﬁt of endo-
vascular treatment over medical treatment in terms of reduction
of number of antihypertensive drugs required to achieve BP
control was signiﬁcantly blunted in the patients with diabetes
mellitus. At variance, there were no differences of SDM for sys-
tolic and diastolic BP, and sCr, analysed according to the base-
line features of the patients (age, percentage of diabetics,
smokers, bilateral stenosis among patients, SBP, diastolic BP,
mean sCr and mean number of drugs).
DISCUSSION
The results of 12 observational trials herein reviewed support,
in our view, the conclusion that PTRA with or without stent-
ing does not harm the kidney and/or preclude achievement of
a better control of BP, but rather the opposite. However, unfor-
tunately by no means, did they provide a conclusive answer as
to whether PTRA is better than optimal medical therapy,
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F IGURE 1 : Forest plot showing the SDMs with 95% CI for systolic BP (Panel A), diastolic BP (Panel B) and drug requirement (Panel C) in
the endovascular treatment arm versus medical therapy arm in different studies. Relative weight shows the impact of every single trial,
proportional to number of patients enrolled.
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either in the entire population of ARAS patients or in the
high-risk subgroups as the diabetics.
Some responses, however, came from the meta-analysis in-
cluding a novel one that included all available RCTs and also
the most recently published [25].
Effect of treatment on BP
Two smaller meta-analyses [30, 31] of three older trials
(EMMA, SNRASCG and DRASTIC) demonstrated a mild
beneﬁt on BP control, but these results were not conﬁrmed
by the two larger meta-analyses [32, 33] that included
STAR and ASTRAL. In the latter study, the number of
patients was 403 in each arm, but because of dropouts only
82% in the medical arm and 86% in the PTRAS arm were
available at 1-year follow-up [24]. The high dropout rate,
ranging from 1 to 10%, seen also in the other trials, suggests
that a selection bias affected their results. This is why to
avoid an untoward effect of the high dropout rate and to
obtain a more realistic weight of the impact of each trial,
only the patients available at follow-up were considered in
our meta-analysis.
This meta-analysis differs from previous meta-analyses
[30–33] not only for including more RCTs, but also excluding
the selection bias due to dropouts. Of note, our enlarged meta-
analysis showed that diastolic BP was signiﬁcantly better con-
trolled in patients treated with revascularization than in those
assigned to medical treatment only (Figure 1, Panel B). This
important ﬁnding was altogether evident notwithstanding the
major impact, due to a much higher sample size than of all
other ﬁve RCTs, of the widely criticized ASTRAL study [24,
34–36] and the just published CORAL study [25]. It is worth
noting that both of these studies enrolled patients who were
not necessarily hypertensive, which could explain their nega-
tive results as revascularization of normotensive patients has
little chances to lower an already normal BP.
In keeping with the previously published meta-analyses,
our meta-analysis could not show a signiﬁcantly greater fall in
SBP in the PTRAS arm (Figure 1, Panel A). This negative
ﬁnding could be explained on multiple grounds: revasculariza-
tion would lower BP if hypertension was caused by the ARAS
alone, which most likely is the pressor mechanism only early
in the course of ARAS. Moreover, SBP is a composite pheno-
type that derives from several other factors, including the highly
prevalent isolated systolic hypertension due to large artery stif-
fening [37]. In the CORAL trial [25], which had the largest rela-
tive weight on the meta-analysis, the patients were recruited
based only on SBP, which led to including many patients with
isolated systolic hypertension, in whom the lowering of BP
could be negligible, particularly, if they were old and/or had a
long-standing history of high BP.
F IGURE 2 : Forest plot showing the SDMs with 95% CI for serum creatinine in endovascular treatment arm versus medical therapy arm in
different studies. Relative weight shows the impact of every single trial, proportional to number of patients enrolled.
Table 6. Meta-analysis outcomes
Systolic and diastolic BP
Renal function
Number of antihypertensive drugs
Incidence of heart failure
Incidence of worsening in renal functiona
Incidence of stroke
Mortality
Cumulative incidence of events
aAn eGFR decrease of ≥20% from basal value, and/or an SCr increase of ≥50%, and/or
need for dialysis.
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The beneﬁcial effects of endovascular treatment on BP could
be prominent in bilateral stenosis, as found in SNRASCG study,
the only RCT that analysed separately patients with unilateral
and bilateral stenosis.
Effect of treatments on need of antihypertensive
drugs and renal function
The lower diastolic BP in the revascularization group evi-
denced by our meta-analysis is an important result that has to
be further emphasized, because it occurred in spite of a greater
reduction of the number of antihypertensive agents at follow-up
in the endovascular treatment than in medical treated arm
(Figure 1, Panel C). This ﬁnding agrees with the conclusions
of all previous meta-analyses [32, 33] of the four studies
(DRASTIC, STAR, ASTRAL, and NITER) for which suitable
information on drug treatment regimen was available.
Assessing the change of antihypertensive drugs needed at
follow-up is a key piece of information for judging the effect of
each treatment not only on BP, but also on renal function,
because a successful revascularization can allow use of drugs,
such as ACE inhibitors, angiotensin receptors blockers or
renin inhibitors, which are often avoided in patients with bilat-
eral ARAS, or with ARAS in a solitary kidney, given the
inherent risk of inducing acute renal failure. Moreover, after a
successful PTRAS, the reduction in number and/or doses of
antihypertensive drugs that raise the GFR could bias the as-
sessment of the effect of endovascular treatment on renal func-
tion. These considerations might explain why we could
evidence only a favourable trend in preserving or improving
renal function with endovascular treatment, a ﬁnding that
differs from the improvement seen in the observational studies
[9, 10, 12–14]. The different selection criteria used might also
explain these divergent results: in two studies [9, 10], 89% of
the 65 patients had bilateral stenosis, whereas in most meta-
analysed RCTs, the majority of the patients had unilateral ste-
nosis. Moreover, many of them did not have even mild CKD
and some (ranging from 5% to 60%) had diabetes mellitus.
Exclusion of CKD patients, who have a higher likelihood of
improving after PTRAS, minimized the chances of ﬁnding
advantages on renal function with revascularization [38].
Inclusion of diabetics, whose renal function can deteriorate re-
gardless of the ARAS, could have diminished differences
between treatment arms, particularly in the RCTs where the
allocation of diabetics to either treatment was unbalanced.
Consistently with this contention by reviewing retrospectively
the effects of surgical revascularization in diabetic and non-
diabetic patients, Hansen et al. found that diabetics had a sig-
niﬁcantly lower rate of beneﬁcial BP response, alongside an in-
creased risk of dialysis or death during follow-up [39].
Our ﬁnding of a decreased need for antihypertensive drugs
with endovascular treatment has profound implications from
the pharmaco-economic standpoint because of the costs of a
long-standing polytherapy and also for clinical practice given
that there is an inverse relationship between number of antihy-
pertensive drugs needed to control BP and patients’ adherence
to treatment [40].
Besides these considerations, some even more important
concerns exist: it is well known that sCr-based eGFR is inac-
curate for estimating early renal dysfunction. This is even
more so in the baseline evaluation of renovascular disease
with/without treatment in that the stenotic kidney has a
reduced GFR, whereas the contralateral likely undergoes high
BP-induced hyperﬁltration. After PTRAS, the GFR increases
in the treated kidney and decreases in the contralateral kidney,
because of the fall in BP [13]. Due to these divergent effects on
the two kidneys, it is altogether unlikely that overall estimates
F IGURE 3 : Meta-regression of percentage of diabetic patients on SDMs of number of drugs in different studies.
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of GFR can show any differences between PTRAS and medical
treatment. Accordingly, it comes as no surprise that eGFR did
not show any improvement after PTRAS [6, 8, 13, 15, 17, 18,
21]. The beneﬁt of stenting could instead be detected by esti-
mating GFR separately in the two kidneys as planned in the
Medical and Endovascular Treatment of Atherosclerotic Renal
Artery Stenosis (METRAS study, http: //clinicaltrials.gov/ct2/
show/NCT01208714) [29]. This now-recruiting RCT is aimed
at comparing PTRAS on top of an optimized medical therapy
targeted to most cardiovascular risk factors with such opti-
mized medical therapy alone.
Endovascular and medical treatment effect
on incidence of events
According to the AHA guidelines, PTRAS should be per-
formed in patients with unexplained heart failure, ﬂash pul-
monary oedema, and refractory or unstable angina [26], thus
implying that revascularization is superior to medical treat-
ment for preventing/regressing these complications. In fact, an
improvement of symptoms was reported after PTRAS in
patients with angina and with heart failure [41]. However, our
meta-analysis showed a trend toward a lower rate in the
PTRAS arm of major events, including acute decompensated
heart failure, worsening renal function, stroke, mortality and
their composite in keeping with previous results [32]. It is,
nonetheless, important to underline that most of meta-
analysed RCTs excluded the sickest patients beforehand (for
example those with heart failure, pulmonary oedema, and re-
fractory angina), because they had compelling indications to
revascularization according to the guidelines [26]. This strat-
egy obviously minimized the chances of showing any beneﬁt
with either treatment. Furthermore, the length of follow-up in
all the meta-analysed RCTs was probably too short to provide
enough statistical power for a proper assessment of the effect
of each treatment on renal and cardiovascular events and mor-
tality. Our meta-analysis did not obviate to this problem as we
could analyse only changes at 1-year follow-up.
Effects of confounders on endpoints
We used meta-regression to adjust for the effect of potential
confounders. This analysis showed a signiﬁcant inverse re-
lationship between the change of number of drugs from base-
line and percentage of diabetics in the study populations
(Figure 3). This result indicates that the higher the rate of dia-
betics in the population the lower the reduction (of SDM) of
the number of necessary antihypertensive drugs, and thereby
the difference between endovascular and medical treatment
arm during follow-up. It suggests that also in the renovascular
microcirculation, like in the coronary vasculature [42–44], the
diabetic microangiopathy can hamper the outcome of success-
ful revascularization on BP control [45].
Limitations
To preserve the balanced distribution of known and
unknown potential confounders between treatment arms pro-
vided by the randomization, all RCTs (except EMMA and
SNRASCG trials [18, 20]) and meta-analyses, including ours,
used an intention-to-treat approach. However, a substantial
percentage of patients assigned to the medical treatment arm
were revascularized, leading to a high crossover rate (Table 4),
and thus biasing the interpretation of results. For example, in
the DRASTIC trial, 44% of the patients in the medical therapy
arm underwent PTRA. This is a further issue that suggests
caution before drawing conclusions concerning equivalence or
superiority of either treatment, as it minimized the chances of
detecting any advantages of revascularization over medical
therapy. It is also probable that the tight inclusion criteria and
the short follow-up did not provide enough power to demon-
strate signiﬁcant differences of SBP, sCr and incidence of
adverse cardiovascular events between endovascular and
medical arms.
CONCLUSIONS
The results of observational studies overall indicate that PTRA
with or without stenting neither precludes achievement of an
improved BP control nor harms the kidney but, if any, the op-
posite.
A meta-analysis of all available RCTs comparing endovas-
cular treatment with medical therapy showed that the former
allows a lowering of the antihypertensive treatment and, not-
withstanding this, is associated with a better control of dias-
tolic BP at follow-up. Whether patients with diabetes mellitus
represent a cohort at higher risk that mandates a more aggres-
sive revascularization strategy needs to be addressed in speciﬁc
RCTs as available literature does not provide any conclusive
evidence.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford
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ACKNOWLEDGEMENTS
We thank Scarpioni R. and coworkers for kindly providing
data about not yet published NITER trial.
FUNDING
This study was supported by research grants from the
Foundation for Advanced Research in Hypertension and
Cardiovascular Diseases (F.O.R.I.C.A., www.forica.it), and the
International PhD Program in Arterial Hypertension and
Vascular Biology of the University of Padua.
CONFLICT OF INTEREST STATEMENT
None declared.
F
U
L
L
R
E
V
IE
W
A t h e r o s c l e r o t i c r e n o v a s c u l a r h y p e r t e n s i o n 551
 at U
niversitÃ  degli Studi di Padova on June 27, 2015
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
REFERENCES
1. Krijnen P, van Jaarsveld BC, Steyerberg EW et al. A clinical prediction
rule for renal artery stenosis. Ann Intern Med 1998; 129: 705–711
2. Montecucco F, Pende A, Mach F. The renin-angiotensin system modulates
inﬂammatory processes in atherosclerosis: evidence from basic research
and clinical studies. Mediat Inﬂamm 2009; 2009: 752406
3. Olin JW. Role of duplex ultrasonography in screening for signiﬁcant renal
artery disease. Urol Clin North Am 1994; 21: 215–226
4. Paul JF, Cherrak I, Jaulent MC et al. Interobserver variability in the
interpretation of renal digital subtraction angiography. AJR Am J Roent-
genol 1999; 173: 1285–1288
5. Grüntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet
1978; 1: 263
6. Cognet F, Garcier JM, Dranssart M et al. Percutaneous transluminal renal
angioplasty in atheroma with renal failure: long-term outcomes in 99
patients. Eur Radiol 2001; 11: 2524–2530
7. Alhadad A, Mattiasson I, Ivancev K et al. Predictors of long-term ben-
eﬁcial effects on blood pressure after percutaneous transluminal renal an-
gioplasty in atherosclerotic renal artery stenosis. Int Angiol 2009; 28:
106–112
8. Dichtel LE, Gurevich D, Rifkin B et al. Renal artery revascularization in
patients with atherosclerotic renal artery stenosis and impaired renal func-
tion: conservative management versus renal artery stenting. Clin Nephrol
2010; 74: 113–122
9. Harden PN, MacLeod MJ, Rodger RS et al. Effect of renal-artery stenting
on progression of renovascular renal failure. Lancet 1997; 349: 1133–1136
10. Watson PS, Hadjipetrou P, Cox SV et al. Effect of renal artery stenting on
renal function and size in patients with atherosclerotic renovascular
disease. Circulation 2000; 102: 1671–1677
11. Muray S, Martín M, Amoedo ML et al. Rapid decline in renal function re-
ﬂects reversibility and predicts the outcome after angioplasty in renal
artery stenosis. Am J Kidney Dis 2002; 39: 60–66
12. Leertouwer TC, Derkx FH, Pattynama PM et al. Functional effects of renal
artery stent placement on treated and contralateral kidneys. Kidney Int
2002; 62: 574–579
13. Coen G, Moscaritolo E, Catalano C et al. Atherosclerotic renal artery ste-
nosis: one year outcome of total and separate kidney function following
stenting. BMC Nephrol 2004; 5: 15
14. Zeller T, Frank U, Müller C et al. Predictors of improved renal function
after percutaneous stent-supported angioplasty of severe atherosclerotic
ostial renal artery stenosis. Circulation 2003; 108: 2244–2249
15. Zeller T, Frank U, Müller C et al. Stent-supported angioplasty of severe
atherosclerotic renal artery stenosis preserves renal function and improves
blood pressure control: long-term results from a prospective registry of
456 lesions. J Endovasc Ther 2004; 11: 95–106
16. Rivolta R, Bazzi C, Stradiotti P et al. Stenting of renal artery stenosis: is it
beneﬁcial in chronic renal failure? J Nephrol 2005; 18: 749–754
17. Kalra PA, Chrysochou C, Green D et al. The beneﬁt of renal artery stent-
ing in patients with atheromatous renovascular disease and advanced
chronic kidney disease. Catheter Cardiovasc Interv 2010; 75: 1–10
18. Plouin PF, Chatellier G, Darne B et al. BP outcome of angioplasty in ather-
osclerotic renal artery stenosis: a randomized trial. Essai Multicentrique
Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998;
31: 823–829
19. Zeller T, Müller C, Frank U et al. Gold coating and restenosis after
primary stenting of ostial renal artery stenosis. Catheter Cardiovasc Interv
2003; 60: 1–6
20. Webster J, Marshall F, Abdalla M et al. Randomised comparison of percu-
taneous angioplasty vs continued medical therapy for hypertensive
patients with atheromatous renal artery stenosis. Scottish and Newcastle
Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998; 12:
329–335
21. Van Jaarsveld BC, Krijnen P, Pieterman H et al. The effect of balloon an-
gioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch
Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J
Med 2000; 342: 1007–1014
22. Katzen BT, Chang J, Lukowsky GH et al. Percutaneous transluminal an-
gioplasty for treatment of renovascular hypertension. Radiology 1979;
131: 53–58
23. Bax L, Woittiez AJ, Kouwenberg HJ et al. Stent placement in patients with
atherosclerotic renal artery stenosis and impaired renal function: a ran-
domized trial. Ann Intern Med 2009; 150: 840–848
24. Wheatley K, Ives N, Gray R et al. Revascularization versus medical therapy
for renal-artery stenosis. N Engl J Med. 2009; 361: 1953–1962
25. Cooper CJ, Murphy TP, Cutlip DE et al. Stenting and medical
therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014; 370:
13–22
26. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Practice Guide-
lines for the management of patients with peripheral arterial disease
(lower extremity, renal, mesenteric, and abdominal aortic): a collaborative
report from the American Association for Vascular Surgery/Society for
Vascular Surgery, Society for Cardiovascular Angiography and Interven-
tions, Society for Vascular Medicine and Biology, Society of Interventional
Radiology, and the ACC/AHATask Force on Practice Guidelines (Writing
Committee to Develop Guidelines for the Management of Patients With
Peripheral Arterial Disease): endorsed by the American Association of
Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and
Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society
Consensus; and Vascular Disease Foundation. Circulation 2006; 113:
e463–752654
27. Scarpioni R, Michieletti E, Cristinelli L et al. Atherosclerotic renovascular
disease: medical therapy versus medical therapy plus renal artery stenting
in preventing renal failure progression: the rationale and study design of a
prospective, multicenter and randomized trial (NITER). J Nephrol 2005;
18: 423–428
28. da Costa Santos CM, de Mattos Pimenta CA, Nobre MR. The PICO strat-
egy for the research question construction and evidence search. Rev Lat
Am Enfermagem 2007; 15: 508–511
29. Rossi GP, Seccia TM, Miotto D et al. The medical and endovascular treat-
ment of atherosclerotic renal artery stenosis (METRAS) study: rationale
and study design. J Hum Hypertens 2012; 26: 507–516
30. Ives NJ, Wheatley K, Stowe RL et al. Continuing uncertainty about the
value of percutaneous revascularization in atherosclerotic renovascular
disease: a meta-analysis of randomized trials. Nephrol Dial Transpl 2003;
18: 298–304
31. Nordmann AJ, Woo K, Parkes R et al. Balloon angioplasty or medical
therapy for hypertensive patients with atherosclerotic renal artery steno-
sis? A meta-analysis of randomized controlled trials. Am J Med 2003; 114:
44–50
32. Kumbhani DJ, Bavry AA, Harvey JE et al. Clinical outcomes after percuta-
neous revascularization versus medical management in patients with sig-
niﬁcant renal artery stenosis; a meta-analysis of randomized controlled
trials. Am Heart J 2011; 161: 622–630
33. Shetty R, Biondi-Zoccai GG, Abbate A et al. Percutaneous renal artery in-
tervention versus medical therapy in patients with renal artery stenosis: a
meta-analysis. EuroIntervention 2011; 7: 844–851
34. White CJ. Kiss my Astral: one seriously ﬂawed study of renal stenting after
another. Catheter Cardiovasc Interv 2010; 75: 305–307
35. Henry M, Benjelloun A, Henry I et al. Renal angioplasty and stenting: is it
still indicated after ASTRAL and STAR studies? J Cardiovasc Surg 2010;
51: 701–720
36. Sarac TP. Inﬂuence and critique of the ASTRAL and CORAL Trials.
Semin Vasc Surg 2011; 24: 162–166
37. Giannattasio C, Failla M, Hennig M et al. Different relation between 24-h
blood pressure and distensibility at different peripheral arteries. Data from
the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens
2005; 23: 557–562
38. Saﬁan RD, Madder RD. Reﬁning the approach to renale artery revasculari-
zation. J Am Coll Cardiol Cardiovasc Interv 2009; 2: 161–174
39. Hansen KJ, Lundberg AH, Benjamin ME et al. Is renal revascularization
in diabetic patients worthwhile? J Vasc Surg 1996; 24: 383–393
40. Burnier M, Brown RE, Ong SH et al. Issues in blood pressure control and
the potential role of single-pill combination therapies. Int J Clin Pract
2009; 63: 790–798
F
U
L
L
R
E
V
IE
W
552 P. Caielli et al.
 at U
niversitÃ  degli Studi di Padova on June 27, 2015
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
41. Khosla S, White CJ, Collins TJ et al. Effects of renal artery stent implan-
tation in patients with renovascular hypertension presenting with unstable
angina or congestive heart failure. Am J Cardiol 1997; 80: 363–366
42. Vis MM, Sjauw KD, van der Schaaf RJ et al. In patients with ST-segment
elevation myocardial infarction with cardiogenic shock treated with percu-
taneous coronary intervention, admission glucose level is a strong indepen-
dent predictor for 1-year mortality in patients without a prior diagnosis of
diabetes. Am Heart J 2007; 154: 1184–1190
43. Ergelen M, Uyarel H, Cicek G et al. Which is worst in patients
undergoing primary angioplasty for acute myocardial infarction?
Hyperglycaemia? Diabetes mellitus? Or both? Acta Cardiol 2010; 65:
415–423
44. Cicek G, Uyarel H, Ergelen M et al. Hemoglobin A1c as a prognostic
marker in patients undergoing primary angioplasty for acute myocardial
infarction. Coron Artery Dis 2011; 22: 131–137
45. Garovic VD, Textor SC. Renovascular hypertension and ischemic nephro-
pathy. Circulation 2005; 112: 1362–1374
Received for publication: 7.1.2014; Accepted in revised form: 11.3.2014
Nephrol Dial Transplant (2015) 30: 553–559
doi: 10.1093/ndt/gfu089
Advance Access publication 19 April 2014
The ESA scenario gets complex: from biosimilar epoetins
to activin traps
Wolfgang Jelkmann
Institute of Physiology, University of Luebeck, Luebeck, Germany
Correspondence and offprint request to: Wolfgang Jelkmann; E-mail: Jelkmann@physio.uni-luebeck.de
ABSTRACT
Recombinant human erythropoietin (rhEpo, epoetin) has
proved beneﬁcial in preventing transfusion-dependent
anaemia in patients with chronic kidney disease. Apart from
copied epoetins distributed in less regulated markets, ‘biosi-
milar’ epoetins have gained currency in many regions, where
they compete with the originals and with rhEpo analogues
with prolonged survival in circulation (‘biobetter’). Recombi-
nant erythropoiesis stimulating agents are potent and well
tolerated. However, their production is costly, and they must
be administered by the parenteral route. Hence, other anti-
anaemia treatments are being evaluated. Clinical trials are
being performed with stabilizers of the hypoxia-inducible
transcription factors (HIFs), which increase endogenous Epo
production. HIF stabilizers are chemical drugs and they are
active on oral administration. However, there is fear that they
may promote tumour growth. Epo mimetic peptides have
also raised expectations. Yet the prototype peginesatide was
recalled after just 1 year of its widespread use in the USA
because of serious side-effects including cases of death. Most
recently, clinical trials have been initiated with sotatercept, a
recombinant soluble activin receptor type 2A IgG-Fc fusion
protein. Sotatercept binds distinct members of the transform-
ing growth factor-β family, thereby preventing the inhibitory
action of these factors in erythropoiesis. Taken together,
rhEpo and its long-acting recombinant analogues will likely
remain mainstay of anti-anaemia therapies in the near
future.
Keywords: activin, anaemia, biosimilars, chronic kidney
disease, erythropoiesis-stimulating agents
INTRODUCTION
Erythropoietin (Epo) is essential for the growth of colony-
forming units-erythroid (CFU-Es) and other erythrocytic pro-
genitors. Insufﬁcient Epo production contributes to the
anaemia associated with chronic kidney disease (CKD). Treat-
ment with erythropoiesis-stimulating agents (ESAs) can
reduce the requirements for red blood cell (RBC) transfusion.
Recombinant human Epo (rhEpo, epoetin) has been applied
in the renal setting for over 25 years. Recently, copy versions
of epoetins have received marketing authorization in many
regions, including the European Union (EU). In addition,
second-generation rhEpos with improved pharmacokinetic
properties have become therapeutic options.
The administration of rhEpo and its analogues is effective
and rarely associated with serious adverse events (SAEs).
However, recombinant ESAs are expensive and they require a
parenteral route of administration. Hence, alternative
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